Cargando…

Neoadjuvant treatment strategy for locally advanced thoracic esophageal cancer

Multimodal treatment combining surgery with chemotherapy and/or radiotherapy is necessary to improve the chances of survival in patients with locally advanced thoracic esophageal cancer. Based on the results of the Japan Clinical Oncology Group 9907 (JCOG9907) trial, neoadjuvant chemotherapy, two co...

Descripción completa

Detalles Bibliográficos
Autores principales: Mayanagi, Shuhei, Irino, Tomoyuki, Kawakubo, Hirofumi, Kitagawa, Yuko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6524122/
https://www.ncbi.nlm.nih.gov/pubmed/31131355
http://dx.doi.org/10.1002/ags3.12243
_version_ 1783419493069881344
author Mayanagi, Shuhei
Irino, Tomoyuki
Kawakubo, Hirofumi
Kitagawa, Yuko
author_facet Mayanagi, Shuhei
Irino, Tomoyuki
Kawakubo, Hirofumi
Kitagawa, Yuko
author_sort Mayanagi, Shuhei
collection PubMed
description Multimodal treatment combining surgery with chemotherapy and/or radiotherapy is necessary to improve the chances of survival in patients with locally advanced thoracic esophageal cancer. Based on the results of the Japan Clinical Oncology Group 9907 (JCOG9907) trial, neoadjuvant chemotherapy, two courses of cisplatin and 5‐fluorouracil (5‐FU), followed by esophagectomy with D2 lymphadenectomy is the recommended treatment in Japan. Alternatively, neoadjuvant chemoradiotherapy (NACRT) typified by carboplatin and paclitaxel plus concurrent radiotherapy with 41.4 Gy (Chemoradiotherapy for Esophageal Cancer followed by Surgery Study [CROSS]) has shown promising outcomes in some Western countries. Currently, several clinical trials are being conducted within and outside of Japan to confirm the best neoadjuvant treatment regimen. For instance, a three‐arm phase III randomized controlled trial (JCOG1109) is ongoing in Japan. The three arms comprise a doublet regimen (two courses of cisplatin 80 mg/m(2) day 1 and 5‐FU 800 mg/m(2) days 1‐5; repeated every 3 weeks) versus a triplet regimen (three courses of docetaxel, 70 mg/m(2) day 1; cisplatin 70 mg/m(2) day 1; and 5‐FU 750 mg/m(2) days 1‐5; repeated every 3 weeks) versus a chemoradiotherapy (CRT) regimen (radiotherapy of 41.4 Gy/23 fractions with two courses of cisplatin 75 mg/m(2) day 1 and 5‐FU 1000 mg/m(2) days 1‐4; repeated every 4 weeks). Development of a multimodal strategy for neoadjuvant therapy is expected to receive the continuous focus of research in the hope of achieving better outcomes from treatment of patients with advanced thoracic esophageal cancer.
format Online
Article
Text
id pubmed-6524122
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-65241222019-05-24 Neoadjuvant treatment strategy for locally advanced thoracic esophageal cancer Mayanagi, Shuhei Irino, Tomoyuki Kawakubo, Hirofumi Kitagawa, Yuko Ann Gastroenterol Surg Review Articles Multimodal treatment combining surgery with chemotherapy and/or radiotherapy is necessary to improve the chances of survival in patients with locally advanced thoracic esophageal cancer. Based on the results of the Japan Clinical Oncology Group 9907 (JCOG9907) trial, neoadjuvant chemotherapy, two courses of cisplatin and 5‐fluorouracil (5‐FU), followed by esophagectomy with D2 lymphadenectomy is the recommended treatment in Japan. Alternatively, neoadjuvant chemoradiotherapy (NACRT) typified by carboplatin and paclitaxel plus concurrent radiotherapy with 41.4 Gy (Chemoradiotherapy for Esophageal Cancer followed by Surgery Study [CROSS]) has shown promising outcomes in some Western countries. Currently, several clinical trials are being conducted within and outside of Japan to confirm the best neoadjuvant treatment regimen. For instance, a three‐arm phase III randomized controlled trial (JCOG1109) is ongoing in Japan. The three arms comprise a doublet regimen (two courses of cisplatin 80 mg/m(2) day 1 and 5‐FU 800 mg/m(2) days 1‐5; repeated every 3 weeks) versus a triplet regimen (three courses of docetaxel, 70 mg/m(2) day 1; cisplatin 70 mg/m(2) day 1; and 5‐FU 750 mg/m(2) days 1‐5; repeated every 3 weeks) versus a chemoradiotherapy (CRT) regimen (radiotherapy of 41.4 Gy/23 fractions with two courses of cisplatin 75 mg/m(2) day 1 and 5‐FU 1000 mg/m(2) days 1‐4; repeated every 4 weeks). Development of a multimodal strategy for neoadjuvant therapy is expected to receive the continuous focus of research in the hope of achieving better outcomes from treatment of patients with advanced thoracic esophageal cancer. John Wiley and Sons Inc. 2019-03-01 /pmc/articles/PMC6524122/ /pubmed/31131355 http://dx.doi.org/10.1002/ags3.12243 Text en © 2019 The Authors. Annals of Gastroenterological Surgery published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Gastroenterological Surgery This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Articles
Mayanagi, Shuhei
Irino, Tomoyuki
Kawakubo, Hirofumi
Kitagawa, Yuko
Neoadjuvant treatment strategy for locally advanced thoracic esophageal cancer
title Neoadjuvant treatment strategy for locally advanced thoracic esophageal cancer
title_full Neoadjuvant treatment strategy for locally advanced thoracic esophageal cancer
title_fullStr Neoadjuvant treatment strategy for locally advanced thoracic esophageal cancer
title_full_unstemmed Neoadjuvant treatment strategy for locally advanced thoracic esophageal cancer
title_short Neoadjuvant treatment strategy for locally advanced thoracic esophageal cancer
title_sort neoadjuvant treatment strategy for locally advanced thoracic esophageal cancer
topic Review Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6524122/
https://www.ncbi.nlm.nih.gov/pubmed/31131355
http://dx.doi.org/10.1002/ags3.12243
work_keys_str_mv AT mayanagishuhei neoadjuvanttreatmentstrategyforlocallyadvancedthoracicesophagealcancer
AT irinotomoyuki neoadjuvanttreatmentstrategyforlocallyadvancedthoracicesophagealcancer
AT kawakubohirofumi neoadjuvanttreatmentstrategyforlocallyadvancedthoracicesophagealcancer
AT kitagawayuko neoadjuvanttreatmentstrategyforlocallyadvancedthoracicesophagealcancer